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Abstract
Background: An interprofessional medication adherence program (IMAP) for chronic patients was developed and
successfully implemented in the community pharmacy of the Department of ambulatory care and community
medicine (Lausanne, Switzerland). This study assesses the capacity of a physician and a nurse at the infectious
diseases service of a public hospital and of community pharmacists in the Neuchâtel area (Switzerland) to
implement the IMAP in their practice.
Methods: Mixed method, prospective, observational study. Quantitative and qualitative analyses of the implementation
process were conducted following the RE-AIM model (reach, effectiveness, adoption, implementation and maintenance).
Results: Implementation started in November 2014. One physician, one nurse, and five pharmacists agreed to participate.
Healthcare professionals perceived the benefits of the program and were motivated to implement it in their practice
(adoption). Seventeen patients were included in the program; 13 refused to participate. The inclusion of naïve HIV
patients was easier than the inclusion of experienced patients with difficult psychosocial issues (reach).
Pharmacists were engaged in reinforcing patient medication adherence in 25% of interviews (effectiveness). Key
facilitators expressed by healthcare professionals were patient inclusion by the physician and the nurse instead of
the pharmacist and the organisation of regular meetings between all stakeholders. In contrast, the encountered
barriers were the lack of time and resources, the lack of team uptake, and the lack of adoption by senior managers
(implementation). Interviewed patients were all satisfied with this new program, encouraging healthcare professionals to
scale it up. Structural changes allowed the hospital and one pharmacy to enter the maintenance stage (maintenance).
Conclusion: The research team and collaboration between all professionals involved played an important role in this
implementation. However, the dissemination of such a program to a larger scale and for the long term requires financial
and structural resources as well as transitional external support.
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service, Interprofessional collaboration
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Background
Pharmacists are currently developing their role as a pro-
vider of professional pharmacy services through a num-
ber of various initiatives around the world [1]. In
Switzerland, pharmacist interventions such as the poly-
medication check and medication adherence monitoring
are remunerated by the healthcare system. However,
even if a remuneration system exists, only a minority of
pharmacists provide these interventions in practice and
initiatives are often not implemented at scale across the
population [2].
This trend is not confined to Switzerland; implementa-
tion of such services in practice remains difficult world-
wide [3]. Recently, new studies adapted the consolidated
framework for implementation research (CFIR) to list all
potential factors that can influence the implementation
of new services in community pharmacies [4, 5]. The
most frequent barriers cited by pharmacists are lack of
time, lack of resources/staff, lack of support/technical
assistance, and inadequate infrastructure in the phar-
macy [2, 3, 6–10]. The lack of motivation and the lack of
benefits perceived by healthcare professionals are bar-
riers that limit the adoption of these new services [2, 8,
11]. Moreover, external factors such as the patients’
needs and acceptance/perception, the lack of collabor-
ation, and the opinion of other healthcare professionals
also influence the implementation of new services [8, 10,
12, 13].
However, examples in the literature show that the im-
plementation of community pharmacy services in practice
is feasible [7, 14]. For example, the Community Pharmacy
Center of the Department of Ambulatory Care & Com-
munity Medicine (PMU) of Lausanne (Switzerland) devel-
oped and successfully implemented an interprofessional
medication adherence program (IMAP) for chronic pa-
tients [15]. The positive impact of this program has
already been demonstrated for HIV patients. However, the
capacity to implement it for HIV patients in other com-
munity pharmacies and medical settings has never been
assessed [16]. To answer this question, an implementation
evaluation study was conducted in 2014 during the imple-
mentation of IMAP in a public hospital “Hôpital neuchâ-
telois, Pourtalès” and community pharmacies in the
Neuchâtel area (Switzerland). The main aim of this re-
search was to evaluate the implementation outcomes of
this project. The second aim was to collect patient clinical
data, in particular medication adherence, viral load (VL),
and CD4 cell count. A full description of the implementa-
tion stages and strategies is given elsewhere [17].
Method
Study design and framework
To evaluate the implementation outcomes at the same
time as the collection of patient clinical data in this
prospective observational study, we used the RE-AIM
model with a mixed method approach [18]. This model
was used to evaluate the transfer of the IMAP into the
current health system and its effectiveness for the target
population through five dimensions: reach, effectiveness,
adoption, implementation (fidelity), and maintenance.
Qualitative and quantitative results are presented by
dimension and themes; results from the qualitative ana-
lysis are underlined with dotted lines. The mixed
method approach, particularly the qualitative analysis,
allowed us to describe the factors influencing the dimen-
sions of interest. Considering the definition given by
Curran et al., the study design is characterized as an hy-
brid type 3 design as the implementation outcomes were
the first interest and clinical outcomes were collected for
informative purposes [19].
Description of the intervention and target patients
The IMAP combines motivational interviewing with feed-
back to the patient based on the medication adherence
electronic measure (MEMS™, WestRock, Switzerland).
The core content of the interview between the pharmacist
and the patient is reported to the physician and the nurse.
The development of the program is fully described else-
where [15].
In this project, the target population are HIV patients
whose medication adherence is not ritualized and/or
patients who go through periods of suboptimal adher-
ence. The physician and the nurse follow their patients
to improve and/or stabilize clinical outcomes and medi-
cation adherence to prevent virological failure. Consider-
ing this aim, patient selection criteria for entering the
IMAP were defined by the participating physician and
nurse as either naïve HIV patients, patients with an anti-
retroviral switch or patients with psychosocial issues.
Measured outcomes
The collected outcomes are described in Table 1. The
clinical outcomes, e.g. VL, CD4 counts, and adherence
data, were observed and described at the individual level
as part of the maintenance dimension.
Data collection
Two research investigators (ML and MPS) collected the
qualitative variables during semi-structured focus
groups, organised every 6 months from April 2015 to
December 2016. The interview grids were developed
using the RE-AIM model and adapted over time accord-
ing to the previous focus group results (Additional file 1).
All themes discussed during these interviews are de-
scribed in Additional file 2. During the first year, focus
groups were organised with the physician and the nurse
on the one hand and with pharmacists on the other.
During the second year, they were brought together
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because of the positive atmosphere in the study groups
and the willingness of healthcare professionals to in-
crease their exchange of experience. If one pharmacist
was absent during a focus group, an investigator (ML or
MPS) visited this pharmacist for an individual interview
and used the same interview grid as the one used during
Table 1 Collected quantitative and qualitative outcomes
Dimension and definition [18] Quantitative outcomes Qualitative outcomes Level of
analysis
Reach = The absolute number, proportion,
and representativeness of individuals who
are willing to participate in a given initiative
• Reach rate: percentage of eligible
patients who agree to participate
(Inclusion/number of proposals*100)a
Hospital
• Reasons for proposal Hospital
• Reasons for refusal Hospital
• Number of drop-outs Pharmacies
• Characteristics of the HIV populationb Hospital
• Barriers and facilitators to
including patients
HCPs and patients
• Patients’ selection criteria HCPs
Adoption = The absolute number, proportion,
and representativeness of settings and
intervention agents who are willing to initiate
a program
• Adoption rate: pharmacists involved in
the program among pharmacies of the
Neuchâtel area (as a %age)
Pharmacies
• Number of involved physicians/nurses
in the hospital
Hospital
• Perceived motivation for and
utility of the program
HCPs
Implementation = implementation refers
to the intervention agents’ fidelity to the
various elements of an intervention’s protocolc
• Fidelity: number of delivered interviews,
interval (in days) in between interviews
Pharmacies
• Length of time for patient follow-up
(in months)
Pharmacies
• Time and cost needed to deliver the
intervention
Pharmacies
• Fidelity and adaptationsd
(use of electronic monitors,
motivational interviewing,
and reporting)
HCPs and patients
• Implementation barriers
and facilitators
HCPs and
patients
• Interprofessional
collaboration development
HCPs
Maintenance = The extent to which a
program or policy becomes institutionalized
or part of the routine organizational
practices and policies
• Monitoring of patient inclusion Hospital and
pharmacies
• Inclusion of the IMAP into
the routine activity over
time
HCPs
• Satisfaction (professionals
and patients)
HCPs and patients
Maintenance at the individual level =
the long-term effects of a program on
outcomes 6 months or more after the
most recent intervention contact
• Adherence data Pharmacies
• VL and CD4 counts Hospital
Notes: HCPs = Healthcare professionals = the physician, the nurse, and the five pharmacists included in the project
aEligible patients were determined by the physician and the nurse and therefore considered as the number of proposals in this project
bGender, age, ethnicity, education degree, source of HIV infection, antiretrovirals (ART) description at inclusion, ART line, VL, and CD4 count at inclusion
cIn addition, implementation research has been expanded to include factors influencing the implementation process
dInformation about fidelity and adaptations was collected by the research team through focus groups with HCPs and individual interviews with patients
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the focus group. Patients’ perceptions were also collected
by an investigator during individual, semi-structured,
taped phone interviews. Patient interviews were stopped
after data saturation was reached.
Quantitative variables were collected from October
2014 to December 2016 in patient health records (hos-
pital and pharmacy) and through the Swiss HIV Cohort
Study (SHCS) database, an ongoing multicentre pro-
spective observational study for interdisciplinary
HIV-related research, which includes 69% of all HIV pa-
tients in Switzerland [20]. Variables were also collected
prospectively during medical and adherence assessments
at the hospital and at the pharmacies (SISPha™ Software)
(see Table 1). To answer the question of the representa-
tiveness of included patients, we collected sociodemo-
graphic characteristics, VL, and CD4 counts for all HIV
patients followed by the SHCS at the “Hôpital neuchâte-
lois, Pourtalès”. This data covered 1) included patients,
2) patients who refused the program, and 3) patients to
whom the adherence program was not proposed because
the program was not perceived as necessary by the phys-
ician and the nurse.
Qualitative analysis
Individual and focus groups were transcribed verbatim
identifying healthcare professionals and patients with
numbers to ensure anonymity. Transcriptions were in-
ductively coded by two independent investigators sep-
arately (ML and MPS), who then pooled the codes and
discussed the discrepancies. Lastly, the codes were
grouped into themes. To validate our data, the sug-
gested themes were presented to all stakeholders.
Statistical analysis
Descriptive data were represented as proportions for
discrete variables and by the median and the interquartile
range (IQR) for continuous variables, using Excel and
STATA (StataCorp. 2013. Stata Statistical Software: Release
13. College Station, TX: StataCorp LP). Adherence data for
the entire combined antiretroviral treatment (cART) were
represented as the implementation dimension of adherence.
Implementation of the dosing regimen is defined as the ex-
tent to which a patient’s actual dosing corresponds to the
prescribed dosing regimen [21]. Patients were considered
as adherent if this percentage was ≥90% [22].
Results
The collaboration between the physician, the nurse, and
the five pharmacists started in November 2014. All in-
volved healthcare professionals were interviewed four
times during the two-year study period. Eight patients
(out of 17 included, 5 women – 3 men, median age
36 years [35–40]) were interviewed once. At least one
patient per pharmacy was interviewed, which meant that
all pharmacists were represented. All themes and related
transcribed sentences are presented in Additional file 3.
Reach
In 2 years, the program was proposed to 30 patients
considered as eligible by the physician and the nurse; 17
agreed to participate, which represents a reach rate of
56.7%. The main reasons for proposal were a patient’s
difficult psychosocial context that may affect medication
adherence (n = 15), and the introduction of a new treat-
ment, either a first or subsequent line (n = 9) (see
Table 2). All 9 naïve HIV patients were included in the
program with an acceptance rate of 100%, whereas pa-
tients with psychosocial issues tended to refuse the pro-
gram more often (n = 10/15) (Table 2).
The number of included patients per pharmacy was low
(2 to 3 patients), except for the pharmacist located near
the hospital, who followed 9 patients. The included pa-
tients were mostly men (n = 10; 58.8%) and younger than
patients who refused (median age 36 [31–43]). No drop
out was recorded in the study. Characteristics of the entire
HIV population of the hospital are presented in Table 2.
Facilitators for reaching patients
Facilitators for reaching patients were their inclusion by
the physician and the nurse and specifically the inclusion
of naïve HIV patients, to whom the program was pre-
sented as a package linked to the new treatment. Quan-
titative data confirmed this statement, as 100% of naïve
HIV patients agreed to participate (see Table 2). Accord-
ing to interviewed patients, the physician and the nurse
described the program appropriately and information re-
ceived by patients was reassuring.
Refusals and barriers to reaching patients
The main reported reason for refusal was the patient’s
reluctance to change pharmacy, especially because of an
existing trust relationship with the pharmacist (n = 11/
13). However, the physician and the nurse explained that
reasons were sometimes unclear, a possible escape for
some complex patients who did not want to talk about
their medication adherence. These patients are difficult
to reach; they also tend to avoid talking with the nurse
trained in therapeutic education at the hospital.
Different barriers have been encountered by healthcare
professionals to reach patients. These can be HIV-related
difficulties (psychosocial issues with stigmatisation, denial
and need for a high confidentiality level) and the limited
number of trained pharmacies, reducing the choice for pa-
tients. The small population base of HIV patients also ex-
plained the small number of included patients.
Another factor was non-inclusion by pharmacists who
had difficulties in identifying target patients among their
regular HIV patients and in proposing the program at
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Table 2 Characteristics of the HIV population of the “Hôpital neuchâtelois-Pourtalès” between November 2014 and December 2016
(based on the patients’ medical records for included patients and the data of the Swiss HIV Cohort Study, SHCS, for patients who
refused or were not proposed participation)
Inclusion Refusal Not proposed
Number of patients 17 13 25
Gender (n, %)
Male 10 (58.8%) 5 (38.5%) 15 (60.0%)
Female 6 (35.3%) 5 (38.5%) 10 (40.0%)
Transsexual 1 (5.9%) 0 0
Missing data 0 3 (23.1%) 0
Age (year) (median, IQR) 36 (31–42) 52 (39–56) 49 (41–54)
Ethnicity
White 12 (70.6%) 9 (69.2%) 16 (64.0%)
Black 3 (17.6%) 1 (7.7%) 5 (20.0%)
Other ethnicity 2 (11.8%) 0 4 (16.0%)
Missing data 0 3 (23.1%) 0
Highest attained educational degree (n, %)
Basica 1 (5.9%) 1 (7.7%) 5 (20.0%)
Medium/highb 12 (70.6%) 9 (69.2%) 20 (80.0%)
Unknown/Missing data 4 (23.5%) 3 (23.1%) 0
Most likely source of HIV infection
Sexual contact 13 (76.4%) 8 (61.5%) 22 (88.0%)
I.V. drug use/sexual contact (unclear which one) 2 (11.8%) 1 (7.7%) 3 (12.0%)
Other sources 2 (11.8%) 1 (7.7%) 0
Missing data 0 3 (23.1%) 0
ART description at inclusionc
NRTI + NNRTI 7 (41.2%) 9 (69.2%) 15 (60.0%)
NRTI + INSTI 6 (35.3%) 0 2 (8.0%)
Other 3 (17.6%) 1 (7.7%) 5 (20.0%)
No treatment 0 0 3 (12.0%)
Missing data 1 (5.9%) 3 (23.1%) 0
Switch of treatment during the study (n, %) 7 (41.2%) 4 (30.8%) 6 (24.0%)
Treatment stop 0 1 (7.7%) 1 (4.0%)
Missing data 0 3 (23.1%) 0
ART line
Naive patientsd 9 (53.0%) 0 0
Experienced patients 8 (47.0%) 10 (76.9%) 24 (96.0%)
Missing data 0 3 (23.1%) 1 (4.0%)
VL at inclusion
Patients with < 50 copies/mL (n, %) 7 (41.2%) 10 (76.9%) 24 (96.0%)
Patients with ≥50 copies/mL (n, %) 10 (58.8%) 0 1 (4.0%)
Missing data (n, %) 0 3 (23.1%) 0
CD4 at inclusion (median, IQR)
CD4 count (cell/mm3) 583 (434–687) 753 (659.5–931.5) 648 (406.5–908.5)
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the counter, which could breach the confidentiality
needed by many HIV patients. Moreover, they had diffi-
culties in acknowledging the added value and benefits of
the program and were afraid to propose a “paid service”
to patients, even if the program is supported by the
Swiss national health insurance system.
Adoption
Motivations of healthcare professionals
At the hospital, the initiating event for adopting the IMAP
was a local experience with a non-adherent patient, whose
need for medical and nursing time was disproportionate
compared to the other patients. The physician and the
nurse became aware of the need for additional support,
which spurred them to contact the Lausanne community
pharmacy to implement the IMAP in their practice. The
hierarchy of the infectious disease service was informed of
the program and its development.
In the Neuchâtel area, five community pharmacies
were trained and ready to deliver the program, which
represented 9% of Neuchâtel pharmacies (n = 5/56). Par-
ticipating pharmacists were convinced that such a ser-
vice is part of the future of the profession and perceived
it as an opportunity to prove their added value. The
IMAP, in collaboration with the hospital, was seen as a
springboard and an opportunity to include patients and
get more experience in medication adherence. For all
healthcare professionals, motivations to integrate the
IMAP in their practice were to support complex patients
and to develop interprofessional collaborations.
Perceived utility of the program by healthcare professionals
All healthcare professionals agreed that the program was
useful for patients. Firstly, they observed improvements
in clinical results. Secondly, patients developed a rela-
tionship of trust with the pharmacist, who became a ref-
erence person for the patient at the pharmacy. The
physician also noted that the pharmacist was a contact
point for keeping patients in care and avoiding losing
patients for follow-up. Thirdly, the use of electronic pill-
boxes seemed to reassure patients, allowing them to
visualize their medication intake.
Implementation
Time and cost
The total time needed at the hospital to deliver the pro-
gram was 30 to 40 min per patient (proposal: 5–10 min,
contact with the pharmacist: 15 min, discussion with the
patients about medication adherence results during
follow-up visit: 10–15 min). No specific costs were
required at the hospital to implement the program. For
the physician and the nurse, this new program took
more time at the beginning of the implementation
process, but is now integrated into a routine and does
not require substantial additional time. For pharmacists,
the program delivery took approximately 45 min for a
first interview and 20 to 45 min per patient for a
follow-up interview (interview preparation: 5 min, inter-
view: 5–30 min, report (writing and sending): 10 min).
The regular meetings, organised every 6 months be-
tween stakeholders, took approximately two hours. The
Table 2 Characteristics of the HIV population of the “Hôpital neuchâtelois-Pourtalès” between November 2014 and December 2016
(based on the patients’ medical records for included patients and the data of the Swiss HIV Cohort Study, SHCS, for patients who
refused or were not proposed participation) (Continued)
Inclusion Refusal Not proposed
Reasons for proposal (n, %)e –
Difficult psychosocial context 5 10
Introduction of a new ART 8 1
Difficulties described by the patient 2 1
Suspected non-adherence by health professionals 3 0
Other 1 1
Reasons for patient refusal (n, %)e – –
Refused to change pharmacy 11
Doesn’t feel the need for such support 2
Fears about confidentiality 2
Notes:
a Did not complete school or professional education, mandatory school
b Finished apprenticeship, bachelor’s degree, higher professional education, higher technical or commercial school, university or other equivalent
educational degree
c NRTI = nucleoside reverse-transcriptase inhibitors, NNRTI = non-nucleoside reverse-transcriptase inhibitors, INSTI = integrase inhibitors
d First ART started < 1 month ago
e More than one reason was possible
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rent of the meeting room was zero as the meetings took
place in the hospital.
To implement the program in practice, pharmacists
had to pay 4500 CHF per year for the web platform,
which includes 5 days of training available for the
pharmacist and one day for the pharmacy technician.
Intervention fidelity and adaptations
The intervention consisted of patient-pharmacist moti-
vational interviews based on the medication adherence re-
sults of the electronic monitors, followed by a medication
adherence report sent to the physician and the nurse. In
total, 63 medication adherence interviews were encoded
on the web platform by the pharmacists. The median
interval in between interviews was 48 days [30–73] and
the median follow-up time since inclusion was 1.7 years
[0.6–1.9]. Two pharmacists (2/5) had a high fidelity to the
program. They fully integrated the communication skills
of motivational interviewing, they used the electronic
monitors, and emailed reports on each interview to the
physician and the nurse. The other three pharmacists bal-
anced between a paternalistic and a shared responsibility
attitude with patients. However, with time, most of them
developed active-listening skills, progressed at the patient’s
rhythm, looked for solutions in collaboration with pa-
tients, and valued patients’ self-management achieve-
ments. They connected fluctuations in medication
adherence over time to living conditions, e.g. a drop in
cART adherence during an overwhelming postpartum
period. During the first year, pharmacists expressed fears
about tackling some adherence issues with patients and
thought that patients would perceive the intervention as a
‘policing’ one. This feeling decreased over time and phar-
macists became more at ease with patients.
Only one pharmacist, who followed two patients, did not
use the electronic monitors because neither the patients
nor the pharmacist were at ease with the monitoring and
perceived it as a form of control instead of a support.
Finally, we observed that pharmacists did not system-
atically send the adherence report to the physician and
the nurse. Some pharmacists had concerns about the
relevance of the transmitted information. Moreover,
pharmacists had concerns about disturbing the physician
with too many reports and increasing his workload.
However, all pharmacists contacted the physician or the
nurse in case of medication adherence problems. Even
so, the physician had to express several times his need
for regular medication adherence reports as this dimen-
sion matters and guides the medical patient’s follow-up,
whether medication adherence is high or low. This re-
peated information motivated the pharmacists, who
started sending the report more regularly.
The flow diagrams of the activity as described by the
physician, the nurse, and community pharmacists are
presented in Additional file 4. Compared to the original
IMAP, pharmacies in the Neuchâtel area have not yet in-
tegrated pharmacy technicians into the program.
Implementation facilitators and barriers
The discriminant facilitator was the program’s in-
volvement of the physician and nurse in including pa-
tients and in acknowledging the pharmacist’s role in
supporting medication adherence. The second was the
resources put in place for the program (research sup-
port, web platform, and trainings) and particularly the
regular meetings between stakeholders organised by
the research team. These meetings were an important
step in driving the project forwards. They were de-
scribed as rewarding and stimulating, and allowed
healthcare professionals to get feedback from each
other and exchange experience with their colleagues.
These interprofessional contacts helped them to learn
about each other’s expectations and meet the phys-
ician and the nurse face-to-face, which facilitated
communication in practice. The physician and the
nurse also raised the fact that the small size of the
medical team facilitated internal communication on
including patients at the beginning of the implemen-
tation project.
In contrast, the largest barrier encountered by health-
care professionals was a lack of time, related to lack of
resources. For the physician and the nurse, the lack of
time was a barrier to the program when a patient had
somatic problems that had to be prioritized during the
medical visit. For pharmacists, staff were already
engaged in a full-time workload with the usual pharmacy
activities. Another barrier encountered by pharmacists
was the low adoption by pharmacy managers because of
a lack of sufficient financial incentives. Some pharma-
cists also reported a lack of team uptake. For example,
only one pharmacist was in charge of the program per
pharmacy.
Patients described the time required for interviews as
acceptable as they perceived the benefits of the interven-
tion and they appreciated the organisation of interviews at
the pharmacy. No barrier was encountered by patients.
Development of interprofessional collaboration
The respective roles of each healthcare professional in the
program are described in Fig. 1. All professionals see pa-
tients at different intervals and are complementary to each
other. Five practical benefits of this collaboration were per-
ceived by healthcare professionals. The first was the synergy
and the complementarity of the information given by the
patient to each professional. Second, the pharmacist’s report
was useful for the physician during the medical visit to open
up discussion with patients on medication adherence and
to integrate this information into clinical decisions. Third,
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the program was reassuring for the physician and the nurse
as it strengthens patient safety regarding drug interaction
management, OTCs, and regular treatment delivery.
Fourth, the program was an opportunity to share responsi-
bilities for complex patients, and fifth, an opportunity to de-
crease the risk of patient loss for follow-up.
Maintenance
Monitoring of patient inclusion
Figure 2 shows that refusals occurred only during the
first months of the project and revolved around experi-
enced patients. Based on this initial experience, only
new HIV patients or patients with a switch of treatment
have since been included in the program by the phys-
ician and the nurse.
Inclusion of the program into the routine activity
In May 2016, a structural change at the hospital allowed
all new interns on rotation to stay in the service longer,
i.e. for 6 months. This change allowed the physician and
the nurse to integrate the new intern in the program
and lead the nurse to formalize the IMAP, including it in
the local hospital guidelines. This step represented the
transition to the maintenance stage.
Four pharmacists were in the operation stage at the
end of the project. One pharmacy included a second
Fig. 1 Respective roles of each healthcare professional in the IMAP. Note: ARVs = antiretrovirals
Fig. 2 Patient inclusion monitoring during the two-year follow-up
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pharmacist in the program and implemented a team or-
ganisation, with a shared calendar to organise interviews
with patients. An increase in patient inclusions, includ-
ing patients with other chronic diseases, e.g. diabetes,
has been made possible with this new organisation. This
brings the program into the pharmacy’s routine activity,
and therefore the sustainability stage.
Healthcare professionals’ satisfaction
All healthcare professionals were satisfied with this new
program, considering it as an ideal collaboration and a
new professionally satisfying activity. The positive feed-
back and the acknowledgement received from patients
reinforced their idea that the program improves patient
support. Moreover, as reinforced by pharmacists, the
project was instructive and opened doors to more path-
ologies, such as hepatitis C or type II diabetes.
Patient satisfaction
All interviewed patients (n = 8) had a positive perception
of the program and were satisfied. They all experienced
good collaboration with healthcare professionals and five
patients stated that they had developed a relationship of
trust with them.
Four patients expressed that the interview with the
pharmacist represented additional social support and
reassured them. Five patients also reported that it
allowed them to benefit from a reference person at the
pharmacy. Three patients perceived the interview with
the pharmacist as a new opportunity to discuss their
medication, whereas four stated that they received sup-
port in their treatment management. The four latter
patients reported that they were more aware of the im-
portance of the treatment intake and more active in the
search for solutions in collaboration with healthcare pro-
fessionals. Finally, one patient perceived the feedback
from professionals as encouraging.
Concerning the electronic monitors, six patients stated
that they were satisfied with the electronic monitor,
which reassured them and prevented omissions through
the real time LCD display.
Intervention outcomes
We observed that all 9 naïve HIV patients included in
the program and one experienced HIV patient who was
detectable at inclusion became undetectable during the
follow-up. Only one blip, a temporary detectable in-
crease in viremia (VL), was observed in a patient during
the follow-up. Patients who refused the program were
all undetectable at the moment of the proposal and
stayed undetectable during the entire two-year study
period. Two patients who were not invited to join the
program had a blip during the study period. CD4 counts
are presented in Table 3.
Median adherence during the entire monitoring period
was 99.5% [90–100] and was below 90% in 2 experi-
enced HIV patients. Five patients had transient subopti-
mal adherence (< 90%) in a total of 13 inter-visit periods.
This means that pharmacists were engaged in reinfor-
cing patient medication adherence in 25% (n = 13/52) of
registered interviews.
Discussion
Feasibility
This study showed that the physician and the nurse
at the infectious disease service of the Neuchâtel hos-
pital and local community pharmacists were able to
implement the IMAP in their practice. The program
was clearly adopted by healthcare professionals, who
perceived the benefits of the program for the patient’s
follow up and were motivated to implement it in
their practice. The physician and the nurse were con-
vinced of the positive role of the pharmacist in im-
proving medication adherence and the regular
meetings, which allowed real interprofessional collab-
oration to develop and become ingrained in practice.
The interviewed patients were all satisfied, which
encouraged healthcare professionals to continue to
deliver the program. The external support of the re-
search team and of SISPha was an important factor
in driving the project forward.
Naïve HIV patients were easier to include. Experi-
enced patients with psychosocial context, to whom the
Table 3 Patient CD4 cells counts at inclusion and at the end of the study period
CD4 countsa (cell/mm3) (median, IQR) [95% CI]
At inclusion At the end of the study period
Included patients (n = 10)
Naïve patients (n = 3) 280 (272–374) [272–374] 524 (516–910) [516–910]
Experienced patients (n = 7) 654 (535–1167) [452–1170] 828 (751–882) [473–1043]
Patients who refused the program (n = 9)
Experienced patients 743 (682–970) [642–1011] 836 (712–1031) [639–1232]
Patients who were not invited to join the program (n = 22)
Experienced patients 697 (496–910) [496–910] 685.5 (502–851) [502–851]
Notes: This table refers to the available CD4 data in the SHCS and therefore does not represent all the hospital’s patients; a Paired data
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program was proposed as a preventive measure, more
often refused to be included. The stigmatisation existing
around patients with psychosocial troubles may have
hindered their inclusion. These observations brought the
physician and the nurse to keep an eye on patients who
refused the program and to systematically propose the
program to new naïve HIV patients.
The healthcare professionals’ motivation and the posi-
tive perception of the program were facilitators of this
project, even though the lack of motivation and physi-
cian’s program perception are often described as barriers
in the literature [2, 8, 11]. However, a lack of time and
resources, frequently cited in the literature, were also
described as barriers in this project, particularly by phar-
macists [3]. The physician and the nurse cited the lack
of time as a barrier but adapted their practice and in-
cluded this new activity without major effort by formal-
izing their actions. Before the project, the physician and
the nurse were aware of the non-adherence problem and
already discussed it with patients during the medical
visits. Moreover, the total time needed to deliver the
program is lower for them than for pharmacists, which
may explain why pharmacists encountered more difficul-
ties in including it in their practice. Moreover, pharma-
cists faced a financial barrier as they had to develop the
program without extra funding/resources. Indeed, most
HIV patients only had one prescribed medicine formula-
tion combining the entire tritherapy, whereas the Swiss
national insurance system reimburses the pharmacist
polypharmacy service if at least three medicine formula-
tions are prescribed simultaneously.
To implement this program in their practice, pharma-
cists had to endorse a “new position” and had to inte-
grate structurally the professional team who follow the
patients. Pharmacists were not comfortable including
HIV patients at the pharmacy because of confidentiality
issues. Indeed, pharmacists were more at ease when pa-
tients were included by the physician and the nurse in a
hierarchical structure as the program was then perceived
by the patients as a medical prescription. Having newly
joined the interprofessional team, pharmacists still
doubted the credibility of their actions and the relevance
of the transmitted information. These doubts resulted in
irregular reporting of medication adherence to the phys-
ician and nurse. Through regular meetings, the physician
and the nurse took the opportunity to reinforce their ex-
pectation of systematic medication adherence reports,
whatever the patient adherence level (regular, stable,
high vs. low, or decreasing). Consequently, pharmacists
became more confident over time. These results show
that the pharmacists’ nascent position in the team was
strengthened by regular meetings and the active involve-
ment of the physician and the nurse; both were seen as
facilitators by pharmacists. These results can be
highlighted by Bandura’s theory, which provides a con-
ceptual framework for self-efficacy and explaining the
link between social-structural factors and organizational
performance [23]. In this study, the active involvement
of the physician and the nurse (social persuasion), the
exchange of experience with other pharmacists (vicari-
ous experience), and feedback from patients (mastery
experience) improved and reinforced pharmacists’ beliefs
about their capacity to deliver the program over time.
Maintenance and perspectives
In this implementation, the systematization of actions
and the uptake of the team were important to envision
the maintenance of the program in a long-term perspec-
tive. This is aligned with the literature [10, 12]. Despite
the encountered barriers, healthcare professionals con-
tinued to deliver the program and wanted to extend it to
other pathologies. Pharmacists considered it as part of
the future of their profession, but the financial barrier,
which led to a lack of resources and time, may hinder
the long-term development of the program and its de-
velopment to a larger scale. Future strategies should
be developed to maintain the program in place, includ-
ing the improvement of the uptake by the team and
workload organisation. The dissemination of the pro-
gram and important strategies, such as organising
regular meetings, were described and discussed in an-
other article describing the implementation process of
the project [24].
Strengths and limitations
This two-year implementation study that brought infor-
mation on maintenance has some limitations. Firstly, the
number of encoded medication adherence interviews
was probably underestimated as pharmacists were not
consistent in data recording and the reporting. Secondly,
the fidelity of the intervention in motivational interview-
ing was evaluated both through focus groups with
healthcare professionals and in individual interviews
with patients, which allowed us to cross check the quali-
tative data and understand how interviews were deliv-
ered. We used this method to minimize the bias of
self-reporting by healthcare professionals regarding their
practice. The fidelity regarding motivational interviewing
should be further assessed through an additional assess-
ment method (e.g. continuous training and timely su-
pervision according to the recommendations of the
motivational interviewing group [25]). Thirdly, inter-
viewed patients were all satisfied but we cannot exclude
a reporting bias, even though research and not clinical
staff performed the interview and the anonymity of the
answers was guaranteed. Fourthly, the low number of in-
cluded patients made the assessment of the interven-
tion’s effectiveness impossible. Nevertheless, medication
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adherence was suboptimal in 25% inter-visit interviews,
giving frequent opportunities to pharmacists in the com-
munity to discuss and improve medication adherence
issues in collaboration with the patients on a timely
basis. Patient inclusion will continue with the mainten-
ance of the program, allowing us to assess its effective-
ness in the future. Fifthly, regarding the selection of
target patients, all naïve HIV patients were included but
some complex experienced patients were more compli-
cated to include. In such patients, a treatment switch or
a detectable viral load could be timely facilitators to le-
verage their inclusion.
Conclusion
The IMAP is a replicable model that can be adapted to
other settings. This program is transposable to all
chronic patients for whom medication adherence is not
ritualized and/or who are going through difficult adher-
ence periods. The active involvement of the physician
and the nurse and the organisation of regular meetings
between all stakeholders helped to drive the project for-
wards and to significantly improve the interprofessional
collaboration. However, the dissemination of such a pro-
gram to a larger scale requires resources and external
support. Finally, the monitoring of patient inclusion, the
use of the electronic monitors and medication adherence
reporting, and the interprofessional collaboration should
be continuously assessed over time to confirm their
maintenance beyond the first 2-year implementation.
Additional files
Additional file 1: Interview grids developed for focus groups with
health care professionals and individual interviews with patients.
Description of data: Interview grids (translated version) used during focus
groups with health care professionals and individual interviews with
patients. (DOCX 44 kb)
Additional file 2: Content of organised meetings and focus groups
during the operation phase. Description of data: Description of topics
covered during meetings and focus groups with health care
professionals. (DOCX 20 kb)
Additional file 3: Themes inferred during the qualitative analyses and
associated sentences. Description of data: Themes defined by researchers
and associated sentences classified by dimensions and measured
outcomes. (DOCX 54 kb)
Additional file 4: Flow diagram of the IMAP as implemented at the
hospital and in community pharmacies. Description of data: Implemented
activity at the hospital and in community pharmacies as described by
each included health care professional 2 years after implementation start
(1 physician, 1 nurse, 4 pharmacists) (compiled version). (DOCX 73 kb)
Abbreviations
IMAP: Interprofessional medication adherence program; PMU: [Policlinique
Médicale Universitaire] = Department of ambulatory care and community
medicine (Lausanne, Switzeland); VL: Viral load
Acknowledgments
We would like to thank Joanna Moullin for the fruitful discussions about this
project and her guidance in the implementation sciences applied to pharmacy
services. We also would like to thank the SHCS for their contribution to this
work in giving us access to their data. Finally, we would like to thank the
“Fonds Van Buuren & Fondation Jaumotte Demoulin” who gave a grant to M.
Lelubre for the end of her research and thesis.
Funding
Not applicable.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
ML and MS designed the study, and collected and analyzed data. OC and
MG participated in the development of the protocol and the implementation
of the project in the hospital. ML drafted the manuscript and MS assisted in
preparation of the manuscript. KA, CDV, and OB revised the manuscript critically
and give final approval of the manuscript. All authors read and approved the
final manuscript.
Ethics approval and consent to participate
The protocol study was submitted to the Ethics committee of the canton of
Vaud (Switzerland) but they stated that the study was exempt from authorization.
A verbal consent was asked to health care professionals for focus groups, whereas
participating HIV patients were asked to sign a written consent form at the
hospital for the individual interview. A separate protocol was submitted to and
approved by the SHCS to collect data in the SHCS database.
Consent for publication
Not applicable.
Competing interests
O. Bugnon is a member of the advisory board of SISPha. The other authors
declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Community pharmacy, School of Pharmaceutical Sciences, University of
Geneva, University of Lausanne, Geneva, Switzerland. 2Community pharmacy,
Department of ambulatory care and community medicine, University of
Lausanne, Lausanne, Switzerland. 3Department of Pharmacotherapy and
Pharmaceutics, Faculté de Pharmacie, Université libre de Bruxelles (ULB),
Brussels, Belgium. 4Department of Internal Medicine and Infectious Diseases,
Pourtalès Hospital, Neuchâtel, Switzerland.
Received: 30 March 2018 Accepted: 23 October 2018
References
1. Costa FA, Scullin C, Al-Taani G, Hawwa AF, Anderson C, Bezverhni Z, et al.
Provision of pharmaceutical care by community pharmacists across Europe:
is it developing and spreading? J Eval Clin Pract. 2017;23(6):1336–47.
2. Hersberger KE, Messerli M. Development of clinical pharmacy in Switzerland:
involvement of community pharmacists in Care for Older Patients. Drugs
Aging. 2016;33:205–11.
3. Mossialos E, Courtin E, Naci H, Benrimoj S, Bouvy M, Farris K, et al. From
“retailers” to health care providers: transforming the role of community
pharmacists in chronic disease management. Health Policy. 2015;119:628–39
Available from: https://doi.org/10.1016/j.healthpol.2015.02.007.
4. Moullin JC, Sabater-Hernández D, Benrimoj SI. Qualitative study on the
implementation of professional pharmacy services in Australian community
pharmacies using framework analysis. BMC Health Serv Res. 2016;16:439
Available from: http://bmchealthservres.biomedcentral.com/articles/10.1186/
s12913-016-1689-7.
5. Shoemaker SJ, Curran GM, Swan H, Teeter BS, Thomas J. Application of the
Consolidated Framework for Implementation Research to community
pharmacy: A framework for implementation research on pharmacy services.
Lelubre et al. BMC Health Services Research          (2018) 18:874 Page 11 of 12
Res Soc Adm Pharm. 2017;13:905–13 Available from: https://doi.org/10.
1016/j.sapharm.2017.06.001.
6. Niquille A, Lattmann C, Bugnon O. Medication reviews led by community
pharmacists in Switzerland: A qualitative survey to evaluate barriers and
facilitators. Pharm Pract (Granada). 2010;8:35–42.
7. Kaae S, Christensen ST. Exploring long term implementation of cognitive
services in community pharmacies - a qualitative study. Pharm Pract
(Granada). 2012;10:151–8.
8. Marquis J, Schneider MP, Spencer B, Bugnon O, Du Pasquier S. Exploring the
implementation of a medication adherence programme by community
pharmacists: a qualitative study. Int J Clin Pharm. 2014;36:1014–22.
9. Feletto E, Wilson LK, Roberts AS, Benrimoj SI. Building capacity to
implement cognitive pharmaceutical services: quantifying the needs of
community pharmacies. Res Soc Adm Pharm. 2010;6:163–73 Available from:
https://doi.org/10.1016/j.sapharm.2009.08.003.
10. Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Practice change in
community pharmacy: quantification of facilitators. Ann Pharmacother.
2008;42:861–8.
11. Okonta JM, Okonta EO, Ofoegbu TC. Barriers to Implementation of
Pharmaceutical Care by Pharmacists in Nsukka and Enugu metropolis of
Enugu State. J Basic Clin Pharm. 2012;3:295–8 Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3979260&tool=
pmcentrez&rendertype=abstract.
12. Adhien P, Van Dijk L, De Vegter M, Westein M, Nijpels G, Hugtenburg JG.
Evaluation of a pilot study to influence medication adherence of patients
with diabetes mellitus type-2 by the pharmacy. Int J Clin Pharm. 2013;35:
1113–9.
13. Fraeyman J, Foulon V, Mehuys E, Boussery K, Saevels J, De Vriese C, et al.
Evaluating the implementation fidelity of new medicines service for asthma
patients in community pharmacies in Belgium. Res Soc Adm Pharm. 2017;
13:98–108.
14. Garcia-Cardenas V, Benrimoj SI, Ocampo CC, Goyenechea E, Martinez-
Martinez F, Gastelurrutia MA. Evaluation of the implementation process and
outcomes of a professional pharmacy service in a community pharmacy
setting. A case report. Res Soc Adm Pharm. 2017;13:614–27.
15. Lelubre M, Kamal S, Genre N, Celio J, Gorgerat S, Hugentobler Hampai D, et
al. Interdisciplinary medication adherence program: the example of a
university community pharmacy in Switzerland. Biomed Res Int. 2015;2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709610/.
16. Krummenacher I, Cavassini M, Bugnon O, Schneider MP. An interdisciplinary
HIV-adherence program combining motivational interviewing and
electronic antiretroviral drug monitoring. AIDS Care. 2011;23:550–61.
17. Lelubre M, Clerc O, Grosjean M, Amighi K, De Vriese C, Bugnon O.
Implementation of an interprofessional medication adherence program for
HIV patients : description of the process using the framework for the
implementation of services in pharmacy. BMC Health Serv Res. 2018;18:1–8.
18. The RE-AIM [Internet]. [cited 2017 Nov 1]. Available from: http://re-aim.org/
about/
19. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-
Implementation Hybrid Design: Combining Elements of Clinical
Effectiveness and Implementation Research to Enhance Public Health. Med
Care. 2012;50:217–26.
20. Swiss HIV Cohort, Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C,
Günthard H, et al. Cohort profile: the Swiss HIV Cohort study. Int J
Epidemiol. 2010;39:1179–89.
21. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et
al. A new taxonomy for describing and defining adherence to medications.
Br J Clin Pharmacol. 2012;73:691–705.
22. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-
transcriptase inhibitor therapy can Lead to viral suppression. Clin Infect Dis.
2006;43:939–41 Available from: https://academic.oup.com/cid/article-lookup/
doi/10.1086/507526.
23. Wood R, Bandura A. Social cognitive theory of organizational management.
Acad Manag Rev. 1989;14:361–84.
24. Lelubre M, Clerc O, Grosjean M, Amighi K, De Vriese C, Bugnon O, Schneider
M-P. Implementation of an interprofessional medication adherence
program for HIV patients: description of the process using the framework
for the implementation of services in pharmacy. BMC Health Serv Res. 2018;
18:698.
25. Motivational Interviewing Network of Trainers (MINT) [Internet]. [cited 2018
Jan 26]. Available from: www.motivationalinterviewing.org
Lelubre et al. BMC Health Services Research          (2018) 18:874 Page 12 of 12
